Polycystic ovary syndrome in women using valproate: A review

Gynecological Endocrinology

Volumn 24, Issue 10, 2008, Pages 562-570

  Bilo, Leonilda ^a,c   Meo, Roberta ^b  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b Neurology Outpatients Service   (Italy)

^c NONE   (Italy)

Author keywords

Bipolar disorder; Epilepsy; Polycystic ovary syndrome; Review; Valproate

Indexed keywords

ESTROGEN; LITHIUM; TESTOSTERONE; VALPROIC ACID;

AMENORRHEA; APPETITE; BIPOLAR DISORDER; BODY WEIGHT; DRUG USE; DRUG WITHDRAWAL; EPILEPSY; ESTROGEN BLOOD LEVEL; HUMAN; HYPERANDROGENISM; HYPERINSULINEMIA; INSULIN BLOOD LEVEL; INSULIN METABOLISM; MENSTRUAL IRREGULARITY; METABOLIC SYNDROME X; NEUROENDOCRINE DISEASE; NONHUMAN; OBESITY; OLIGOMENORRHEA; OVARY POLYCYSTIC DISEASE; PREVALENCE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REVIEW; RISK FACTOR; SEIZURE; SIDE EFFECT; TESTOSTERONE BLOOD LEVEL;

ANTIMANIC AGENTS; BIPOLAR DISORDER; EPILEPSY; FEMALE; HUMANS; POLYCYSTIC OVARY SYNDROME; PREVALENCE; RISK FACTORS; VALPROIC ACID;

EID: 56549084302     PISSN: 09513590     EISSN: 14730766     Source Type: Journal    
DOI: 10.1080/09513590802288259     Document Type: Review

References (81)

1. Carmina E, Lobo RA. Polycystic ovary syndrome (PCOS): arguably the most common endocrinopathy is associated with significant morbidity in women. J Clin Endocrinol Metab 1999;84:1897-1899.
2. Hull M. Epidemiology of infertility and polycystic ovarian disease: endocrinological and demographic studies. Gynecol Endocrinol 1987;1:235-245.
3. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implication for pathogenesis. Endocr Rev 1997;18:774-800.
4. Conway G, Agrawal R, Betteridge D, Jacobs H. Risk factors for coronary artery disease in lean and obese women with the polycystic ovary syndrome. Clin Endocrinol (Oxf) 1992;37:119-125.
5. Battaglia C, Regnani G, Petraglia F, Primavera M, Salvatori M, Volpe A. Polycystic ovary syndrome: it is always bilateral? Ultrasound Obstet Gynaecol 1999;14:183-187.
6. Franks S. Controversy in clinical endocrinology: diagnosis of polycystic ovary syndrome: in defence of the Rotterdam criteria. J Clin Endocrinol Metab 2006;91:786-789.
7. Taylor AE. Polycystic ovary syndrome. Endocrinol Metab Clin North Am 1998;27:877-902.
8. Zawadzki J, Dunaif A. Diagnostic criteria for polycystic ovary syndrome. Towards a rational approach. In: Dunaif A, Givens J, Haseltine F, Merriam GR, editors. Polycystic ovary syndrome. Boston (MA): Blackwell Scientific; 1992. pp 152-160.
9. Rotterdam PCOS Consensus Workshop. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004;81:19-25.
10. Azziz R. Controversy in clinical endocrinology: diagnosis of polycystic ovarian syndrome: the Rotterdam criteria are premature. J Clin Endocrinol Metab 2006;91:781-785.
11. Geisthovel F. A comment on the European Society of Human Reproduction and Embryology/American Society for Reproductive Medicine consensus of the polycystic ovarian syndrome. Reprod Biomed Online 2003;7:602-605.
12. Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab 2004;89:2745-2749.
13. Asuncion M, Calvo RM, San Millan JL, Sancho J, Avila S, Escobar-Morreale HF. A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. J Clin Endocrinol Metab 2000;85:2434-2438.
14. Diamanti-Kandarakis E, Kouli CR, Bergiele AT, Filandra FA, Tsianateli TC, Spina GG, Zapanti ED, Bartzis MI. A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile. J Clin Endocrinol Metab 1999;84:4006-4011.
15. Sackellares J, Crosby C. Long-term efficacy of valproic acid (VPA) in the treatment of absence seizures. Neurology 1980;30:420.
16. Margraf JW, Dreifuss FE. Amenorrhea following initiation of therapy with valproic acid [abstract]. Neurology 1981;31:151.
17. de Krom MCTFM, Hoppener RJEA, Beukers E. Adverse reactions of sodium valproate: secondary amenorrhea and weight gain [abstract]. Clin Neurol Neurosurg 1985;81:66.
18. Maggio B, Giampietro L. Su alcuni effetti endocrinologici del VPA. Boll Lega It Epil 1987;58/59:205-206.
19. Jones TH. Sodium valproate-induced menstrual disturbances in young women. Horm Res 1991;35:82-85.
20. Isojarvi JIT, Laatikainen TJ, Pakarinen AJ, Juntunen KTS, Myllyla VV. Polycystic ovaries and hyperandrogenism in women taking valproate for epilepsy. N Engl J Med 1993;329:1383-1388.
21. Meo R, Bilo L. Polycystic ovary syndrome and epilepsy: a review of the evidence. Drugs 2003;63:1185-1227.
22. Herzog AG, Seibel MM, Schomer D, Vaitukaitis J, Geshwind N. Temporal lobe epilepsy: an extrahypothalamic pathogenesis for polycystic ovary syndrome? Neurology 1984;34:1389-1393.
23. Herzog AG, Seibel MM, Schomer D, Vaitukaitis JL, Geshwind N. Reproductive endocrine disorders in women with partial seizures of temporal lobe origin. Arch Neurol 1986;43:341-346.
24. Bilo L, Meo R, Nappi C, Annunziato L, Striano S, Colao AM, Merola B, Buscaino GA. Reproductive endocrine disorders in women with primary generalized epilepsy. Epilepsia 1988;29:612-619.
25. Bilo L, Meo R, Valentino R, Buscaino GA, Striano S, Nappi C. Abnormal pattern of luteinizing hormone pulsatility in women with epilepsy. Fertil Steril 1991;55:705-711.
26. Herzog AG, Seibel MM, Schomer DL, Vaitukaitis JL, Geshwind N. Reproductive endocrine disorders in men with partial seizures of temporal lobe origin. Arch Neurol 1986;43:347-350.
27. Isojarvi JIT, Laatikainen TJ, Knip M, Pakarinen AJ, Juntunen KTS, Myllyla VV. Obesity and endocrine disorders in women taking valproate for epilepsy. Ann Neurol 1996;39:579-584.
28. Murialdo G, Galimberti CA, Magri F, Sampaolo P, Copello F, Gianelli MV, Gazzerro E, Rollero A, Deagatone C, Manni R, et al. Menstrual cycle and ovary alterations in women with epilepsy on antiepileptic therapy. J Endocrinol Invest 1997;20:519-526.
29. Murialdo G, Galimberti CA, Gianelli MV, Rollero A, Polleri A, Copello F, Magri F, Ferrari E, Sampaolo P, Manni R, et al. Effects of valproate, phenobarbital, and carbamazepine on sex steroid setup in women with epilepsy. Clin Neuropharmacol 1998;21:52-58.
30. Vainonpaa L, Rattya J, Knip M, Tapanainen J, Pakarinen AJ, Lanning P, Tekay A, Myllyla VV, Isojarvi JI. Valproate-induced hyperandrogenism during pubertal maturation in girls with epilepsy. Ann Neurol 1999;45:444-450.
31. Bauer J, Jarre A, Klingmuller D, Elger C. Polycystic ovary syndrome in patients with focal epilepsy: a study in 93 women. Epilepsy Res 2000;41:167.
32. Khatami R, Henrich W, Bauer M, Heinze T, Schmitz B. The significance of polycystic ovaries in women with epilepsy under treatment with antiepileptic drugs: preliminary results of a prospective observational study [abstract]. Epilepsia 2000;41:143.
33. Bilo L, Meo R, Valentino R, Di Carlo C, Striano S, Nappi C. Characterization of reproductive endocrine disorders in women with epilepsy. J Clin Endocrinol Metab 2001;86:2950-2956.
34. Isojarvi JIT, Tauboll E, Pakarinen AJ, van Parys J, Rattya J, Harbo H, Dale PO, Fauser BC, Gjerstad L, Koivunen R, et al. Altered ovarian function and cardiovascular risk factors in valproate-treated women. Am J Med 2001;111:290-296.
35. Stephen L, Kwan P, Shapiro D, Dominiczak M, Brodie M. Hormone profiles in young adults with epilepsy treated with sodium valproate or lamotrigine monotherapy. Epilepsia 2001;42:1002-1006.
36. Chakravarty A. Preliminary observations on valproate and cystic ovaries. Neurology India 2002;50:106-107.
37. Luef G, Abraham I, Trinka E, Alge A, Windisch J, Daxenbichler G, Unterberger I, Seppi K, Lechleitner M, Kramer G, et al. Hyperandrogenism, postprandial hyperinsulinism and the risk of PCOS in a cross sectional study of women with epilepsy treated with valproate. Epilepsy Res 2002;48:91-102.
38. Luef G, Abraham I, Haslinger M, Trinka E, Seppi K, Unterberger I, Alge A, Windisch J, Lechleitner M, Bauer G. Polycystic ovaries, obesity and insulin resistance in women with epilepsy. A comparative study of carbamazepine and valproic acid in 105 women. J Neurol 2002;249:835-841.
39. Betts T, Yarrow H, Dutton N, Greenhill L, Rolfe T. A study of anticonvulsant medication on ovarian function in a group of women with epilepsy who have only ever taken one anticonvulsant compared with a group of women without epilepsy. Seizure 2003;12:323-329.
40. Otoom S, Nusier M, Hasan M, Hadidi H, Samawi R, Younes A, Darweesh M, Boulatova NR. Association of polycystic ovaries with the use of valproic acid in Jordanian patients. Clin Drug Invest 2003;23:527-532.
41. de Vries L, Karasik A, Landau Z, Phillip M, Kiviti S, Goldberg-Stern H. Endocrine effects of valproate in adolescent girls with epilepsy. Epilepsia 2007;48:470-477.
42. Hamed SA, Hamed EA, Shokry M, Omar H, Abdellah MM. The reproductive conditions and lipid profile in females with epilepsy. Acta Neurol Scand 2007;115:12-22.
43. Prabhakar S, Sahota P, Kharbanda PS, Siali R, Jain V, Lal V, Khurana D. Sodium valproate, hyperandrogenism and altered ovarian function in Indian women with epilepsy: a prospective study. Epilepsia 2007;48:1371-1377.
44. El Khayat HA, Abd El-Basset FZ, Tomoum HY, Tohamy SM, Zaky AA, Mohamed MS, Hakky SM, El Barbary NS, Nassef NM. Physical growth and endocrinal disorders during pubertal maturation in girls with epilepsy. Epilepsia 2004;45:1106-1115.
45. Laidlaw J. Catamenial epilepsy. Lancet 1956;2:1235-1237.
46. Logothetis J, Harner R, Morrell F, Torres F. The role of estrogens in catamenial exacerbations of epilepsy. Neurology 1959;9:352-360.
47. Trampuz V, Dimitrijevic M, Kryzanovski J. [Role of epilepsy in the pathogenesis of ovarian dysfunction]. Neuropsihijatrija 1975;23:179-183.
48. Backstrom T. Epileptic seizures in women related to plasma estrogen and progesterone during the menstrual cycle. Acta Neurol Scand 1976;54:321-347.
49. Rosciszewska D, Dudkiewicz J, Blecharz A. Changes in cytohormonal cervical swabs in epileptic women. Neurol Neurochir Pol 1976;10:255-259.
50. Jensen I, Vaernet K. Temporal lobe epilepsy: follow-up investigation of 74 temporal lobe resected patients. Acta Neurochir 1977;37:173-200.
51. Mattson RH, Kamer JA, Caldwell BV, Cramer JA. Seizure frequency and the menstrual cycle: a clinical study [abstract]. Epilepsia 1981;22:242.
52. Skierska E, Leszczynska-Bystrzanowska J, Gajewski AK. [Risk analysis of menstrual disorders in young women from urban population]. Przegl Epidemiol 1996;50:467-474.
53. Rasgon NL, Altshuler LL, Fairbanks L, Elman S, Bitran J, Labarca R, Saad M, Kupka R, Nolen WA, Frye MA, et al. Reproductive function and risk for PCOS in women treated for bipolar disorder. Bipolar Disord 2005;7:246-259.
54. Rasgon NL, Reynolds MF, Elman S, Saad M, Frye MA, Bauer M, Altshuler LL. Longitudinal evaluation of reproductive function in women treated for bipolar disorder. J Affect Disord 2005;89:217-225.
55. Joffe H, Cohen LS, Suppes T, McLaughlin WL, Lavori P, Adams JM, Hwang CH, Hall JE, Sachs GS. Valproate is associated with new-onset oligoamenorrhea with hyperandrogenism in women with bipolar disorder. Biol Psychiatry 2006;59:1078-1086.
56. Joffe H, Cohen LS, Suppes T, Hwang CH, Molay F, Adams JM, Sachs GS, Hall JE. Longitudinal follow-up of reproductive and metabolic features of valproate-associated polycystic ovarian syndrome features: a preliminary report. Biol Psychiatry 2006;60:1378-1381.
57. O'Donovan C, Graves J, Kusumakar V. Prevalence rates of self-reported menstrual abnormalities and clinical hyperandrogenism of women taking divalproex for bipolar mood disorder [abstract no. 89]. Proceedings of Third Conference on Bipolar Disorder; 1999 June 17-19; Pittsburgh, PA.
58. O'Donovan C, Kusumakar V, Graves G, Bird D. Menstrual abnormalities and polycystic ovary syndrome in women taking valproate for bipolar mood disorder. J Clin Psychiatry 2002;63:322-330.
59. McIntyre RS, Mancini DA, McCann S, Srinivasan J, Kennedy SH. Valproate, bipolar disorder and polycystic ovarian syndrome. Bipolar Disord 2003;5:28-35.
60. Joffe H, Hall JE, Cohen LS, Taylor AE, Baldessarini RJ. A putative relationship between valproic acid and polycystic ovarian syndrome: implications for treatment of women with seizure and bipolar disorders. Harv Rev Psychiatry 2003;11:99-108.
61. Akdeniz F, Taneli F, Noyan A, Yuncu Z, Vahip S. Valproate-associated reproductive and metabolic abnormalities: are epileptic women at greater risk than bipolar women? Prog Neuropsychopharmacol Biol Psychiatry 2003;27:115-121.
62. Bilo L, Meo R. Epilepsy and polycystic ovary syndrome: where is the link? Neurol Sci 2006;27:221-230.
63. Egger J, Brett E. Effects of sodium valproate in 100 children with special reference to weight. Br Med J (Clin Res Ed) 1981;283:577-581.
64. Dinesen H, Gram L, Andersen T, Dam M. Weight gain during treatment with valproate. Acta Neurol Scand 1984;70:65-69.
65. Corman C, Leung N, Guberman A. Weight gain in epileptic patients during treatment with valproic acid: a retrospective study. Can J Neurol Sci 1997;24:240-244.
66. Verrotti A, Basciani F, Morresi S, de Martino M, Morgese G, Chiarelli F. Serum leptin changes in patients who gain weight after therapy with valproic acid. Neurology 1999;53:230-232.
67. Breum L, Astrup A, Gram L, Andersen T, Stokholm K, Christensen N, Werdelin L, Madsen J. Metabolic changes during treatment with valproate in humans: implication for untoward weight gain. Metabolism 1992;41:666-670.
68. Vorum H, Gram L, Honore B. Valproate and palmitate binding to serum albumin in valproate-treated patients. Relation to obesity. Epilepsy Res 1993;16:55-64.
69. Roste L, Tauboll E, Isojarvi J, Pakarinen AJ, Huhtaniemi I, Knip M. Effects of chronic valproate treatment on reproductive endocrine function in female and male Wistar rats. Reprod Toxicol 2002;16:767-773.
70. Tauboll E, Roste L, Svalheim S, Gjerstad L. Disorders of reproduction in epilepsy - what can we learn from animal studies? Seizure 2008;17:120-126.
71. Jacobsen N, Halling-Sorensen B, Birkved F. Inhibition of human aromatase complex (CYP19) by antiepiletic drugs. Toxicol In Vitro 2008;22:146-153.
72. Nelson-Degrave VL, Wickenheisser JK, Cockrell JE, Wood JR, Legro RS, Strauss JF III, McAllister JM. Valproate potentiates androgen biosynthesis in human ovarian theca cells. Endocrinology 2004;145:799-808.
73. Wood JR, Nelson-Degrave VL, Jansen E, McAllister JM, Mosselman S, Strauss JF III. Valproate-induced alterations in human theca cell gene expression: clues to the association between valproate use and metabolic side effects. Physiol Genomics 2005;20:233-243.
74. Pylvanen V, Knip M, Pakarinen AJ, Kotila M, Turkka J, Isojarvi JIT. Serum insulin and leptin levels in valproate-associated obesity. Epilepsia 2002;43:514-517.
75. Pylvanen V, Pakarinen A, Knip M, Isojarvi J. Characterization of insulin secretion in valproate-treated patients with epilepsy. Epilepsia 2006;47:1460-1464.
76. Verrotti A, Basciani F, De Simone M, Trotta D, Morgese G, Chiarelli F. Insulin resistance in epileptic girls who gain weight after therapy with valproic acid. J Child Neurol 2002;17:265-268.
77. Ding MP, Bao YY, Chen Z, Liu ZR, Xu LL. [Insulin resistance in epileptic patients during treatment of valproic acid]. Zhejiang Da Xue Xue Bao Yi Xue Ban 2004;33:216-218.
78. Aydin K, Serdaroglu A, Okuyaz C, Bideci A, Gucuyener K. Serum insulin, leptin, and neuropeptide Y levels in epileptic children treated with valproate. J Child Neurol 2005;20:848-851.
79. Tan H, Orbak Z, Kantarci M, Kocak N, Karaca L. Valproate-induced insulin resistance in prepubertal girls with epilepsy. J Pediatr Endocrinol Metab 2005;18:985-989.
80. Meo R, Bilo L, Nappi C, Tommaselli AP, Valentino R, Nocerino C, Striano S, Buscaino GA. Derangement of the hypothalamic GnRH pulse generator in women with epilepsy. Seizure 1993;2:241-252.
81. Klipstein KG, Goldberg JF. Screening for bipolar disorder in women with polycystic ovary syndrome: a pilot study. J Affect Disord 2006;91:205-209.